Latest adenosine Stories
DEERFIELD, Ill., June 24 /PRNewswire/ -- Astellas Pharma US, Inc.
Inotek Pharmaceuticals Corporation announced today that it has begun enrollment in a Phase 1 clinical trial with the Company's selective Adenosine 1 agonist, INO-8875, for the treatment of glaucoma. In March, Inotek received approval from the U.S.
People who must stay awake for long shifts â€“ soldiers, pilots, truckers, students, doctors, parents of newborns â€“ may take comfort from new research showing that preventing the gas nitric oxide from building up in the brain may ward off the sleep urge.
Swiss researchers have identified a gene variation that might explain why some of us are sound sleepers, and some are not.
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.